Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report

Fig. 1

Plasma levels of tamoxifen and metabolites before and after rifampin administration. Blood samples were obtained prior to rifampin treatment with baseline collected right before rifampin initiation. Follow-up samples were collected 2 and 10 weeks post-rifampin discontinuation. Plasma concentrations of tamoxifen and endoxifen (a) and primary metabolites, NDM-tamoxifen and 4-OH-tamoxifen (b) were measured from each blood sample. Horizontal shaded region in (a) depicts the sub-therapeutic range. Vertical shaded region in (a) and (b) depicts the time period of rifampin treatment

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us